Improving Case Definitions for Severe Malaria

Nicholas M. Anstey*, Ric N. Price

The lack of a “gold standard” definition for severe malaria has been a longstanding problem for both clinicians and researchers. The definitions currently used comprise a set of clinical and laboratory parameters associated with an increased risk of death [1,2], combined with the presence of *Plasmodium falciparum* parasitemia [2,3]. In young children, these criteria are predominantly altered consciousness, severe anemia, and respiratory distress [1,3]; a broader range of criteria is applicable to adolescents and adults [2].

While these criteria are sensitive in diagnosing severe malaria, they are also present in other serious illnesses. Since asymptomatic parasitemia is common in malaria-endemic areas, patients fulfilling current World Health Organization (WHO) criteria for severe malaria [3] often have disease attributable to another cause, such as bacterial sepsis with incidental parasitemia [4], thereby limiting the specificity of this definition.

For a treating clinician, a sensitive but less specific definition of severe malaria is entirely appropriate. However, for research purposes, a sensitive clinical definition may not necessarily be appropriate, and the case definition should depend on the research question.

For example, in a recent randomized controlled trial of quinine versus artesunate for severe malaria [5], the aim was to compare the efficacy of two drugs in real-world resource-poor clinical settings. The primary endpoint, mortality, included all patients enrolled with a bedside clinical diagnosis of severe malaria, who were positive for *P. falciparum* by a rapid diagnostic test. This sensitive but less specific definition had clinical applicability, but necessitated a large sample size to overcome the loss of power from the inclusion of patients with less severe disease or severe illness unrelated to malaria.

At the other end of the spectrum, studies of severe malaria pathophysiology require definitions with much higher specificity to ensure accurate identification of mechanisms of disease; sensitivity is less important in these situations. Such specificity in severe malaria has been improved using extended laboratory criteria, lumbar puncture, indirect ophthalmoscopy [6], autopsy validation [7], and a high parasite density threshold [2,8].

**Defining Severe Malaria Cases in Community Intervention Studies**

What definition for severe malaria should be used when severe malaria is a study endpoint rather than an entry criterion? In vaccine trials or intervention studies designed to prevent severe disease, case definitions should reflect a balance between sensitivity and specificity. Neither of the definitions described above would be optimal. Ideally, a level of specificity would be adopted that ensures an accurate estimate of vaccine efficacy, without reducing the sensitivity to a level that requires a major increase in the sample size.

In this issue of *PLoS Medicine*, Philip Bejon et al. present an important study in which they adopt a new approach to balancing the sensitivity and specificity of criteria for severe malaria [9]. The authors define malaria attributable fractions (MAFs) [10] for different case definitions of severe malaria in children in Kenya, which estimate the positive predictive value for severe malaria for a given background prevalence of asymptomatic parasitemia, i.e., the proportion of severe disease with parasitemia that is attributable to malaria.

Using a sample of 4,583 community-based children with asymptomatic parasitemia and 1,422 hospitalized children with signs of severe malaria, the risk of severe disease was modeled using logistic regression with varying parasite densities and a range of comorbidities that may have altered the specificity of their definition of severe malaria. In their coastal Kenyan setting, they calculated that an overall MAF of 95% could be achieved by applying a threshold parasitemia of more than 0.00001.

---

**Linked Research Article**

This Perspective discusses the following new study published in *PLoS Medicine*:

Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, et al. (2007) Defining childhood severe falciparum malaria for intervention studies. *PLoS Med* 4: e251. doi:10.1371/journal.pmed.0040251

The accepted definition of severe malaria is appropriate for clinical purposes, but Philip Bejon and colleagues show that its specificity in clinical trials may be improved by applying a parasite density threshold and by excluding children with certain conditions.

---

The Perspectives section is for experts to discuss the clinical practice or public health implications of a published article that is freely available online.
2,500 parasites/μl after excluding children with meningitis, clinician-diagnosed lower respiratory infection, bacteremia, and gastroenteritis with severe dehydration.

The authors’ rigorous analysis shows what can be achieved with large datasets derived from meticulous prospective collection of clinical and laboratory information. The study included data on asymptomatic parasitemia from settings with different transmission intensity. The researchers were able to collect blood cultures from all hospitalized children, and HIV status was available for almost all.

Despite the strengths of the study, there are some limitations. The absence of indirect ophthalmoscopy [6] (although this is not a widely available procedure) and of cerebrospinal fluid examination in 22% of children with signs of cerebral malaria may have reduced the positive predictive values of their definition. A MAF of 32% for children with high parasitemia and confirmed meningitis could imply a contributory role of malaria to meningitis, and vice versa, but could also indicate some inaccuracy of the MAF in estimating the true burden of severe malaria.

In areas of high malaria transmission, the parasitemic thresholds for defining severe disease will increase. Interestingly, in Kilifi, the thresholds defining uncomplicated and severe malaria were similar. If confirmed elsewhere, this raises the possibility that when parasite density thresholds are available for uncomplicated malaria [10] but not for severe disease, the former could potentially be applied to the latter.

Recent studies suggest that 30% of falciparum malaria occurs outside Africa, mostly in South and Southeast Asia [11], and often in areas with lower, unstable transmission where severe disease occurs in adults as well as children. Calculation of MAFs will be required for each of these age groups. In these regions *P. vivax* may account for more than 50% of infections and is a likely cause of a significant yet neglected burden of severe disease, particularly severe anemia in children [12]. A similar approach to defining attributable fractions for *P. vivax* infections as that demonstrated for *P. falciparum* will allow a better appreciation of the relative burden of *P. vivax* and other malaria species whose association with severe morbidity is often dismissed [12].

Finally, while the lengthy descriptions of severe malaria included in current WHO guidelines [3] are appropriate for clinical purposes, they lack clarity for research purposes. This is particularly true for case definitions in adults, resulting in the frequent use of “modified WHO criteria” to define severe malaria in published studies [2,5,13]. A parasite threshold to improve specificity in severe anemia was defined for research purposes in the 1990 WHO guidelines [8], but was dropped from the current WHO guidelines [3]. Forthcoming guidelines should more clearly and concisely establish case definitions for severe malaria in both children and adults, suitable for different research purposes in different epidemiological settings.

For malaria prevention trials and disease burden studies, forthcoming WHO guidelines should highlight the utility of Bejon et al.’s MAF approach in developing locally applicable case definitions of severe malaria.

### References

1. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, et al. (1995) Indicators of life-threatening malaria in African children. N Engl J Med 332: 1399–1404.
2. Hien TT, Day NP, Nguyen HP, Nguyen TH, Pham PL, et al. (1996) A controlled trial of artesunate or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 335: 76–85.
3. World Health Organization (2000) Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 (Suppl 1): S1–S90.
4. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, et al. (2005) Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 352: 39–47.
5. Dondorp A, Nosten F, Stepniewska K, Day N, White N, et al. (2005) Artezunate versus quinine for treatment of severe falciparum malaria: A randomised trial. Lancet 366: 717–725.
6. Beare NA, Taylor TE, Harding SP, Lewallen S, Molnneux ME (2006) Malarial retinopathy: A newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 75: 790–797.
7. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JG, et al. (2004) Differentiating the pathologies of cerebral malaria by postmortem parasitic counts. Nat Med 10: 143–145.
8. World Health Organization (1990) Severe and complicated malaria. Trans R Soc Trop Med Hyg 84 (Suppl 2): 1–65.
9. Bejon P, Berkley JA, Mwangi T, Ogada E, Mwangi I, et al. (2007) Defining childhood severe falciparum malaria for intervention studies. PLoS Med 4: e251. doi:10.1371/journal.pmed.0040251
10. Smith TF, Schellenberg JA, Hayes R (1994) Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med 13: 2945–2958.
11. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of *Plasmodium falciparum* malaria. Nature 434: 214–217.
12. Price RN, Tijerina E, Guerra CA, Yeung S, White NJ, et al. (2007) *Vivax* malaria: Neglected and not benign. Am J Trop Med Hyg. In press.
13. Maguire GP, Handjojo T, Pain MC, Kenangalem E, Price RN, et al. (2005) Lung injury in uncomplicated and severe falciparum malaria: A longitudinal study in Papua, Indonesia. J Infect Dis 192: 1966–1974.

### Clinical Implications and Future Research

Bejon et al. have now demonstrated the utility of such methodology in identifying a case definition that appropriately balances sensitivity and specificity for severe malaria in coastal Kenya. Their definition provides a rational endpoint for future vaccine trials and other community-based malaria prevention trials at this site. The authors acknowledge that these findings are applicable to coastal Kenya and cannot necessarily be generalized to other settings. Nevertheless, the approach they have used will pave the way for others to derive locally applicable MAFs and test the generalizability of their findings. Indeed the derivation of MAFs should, where possible, become an intrinsic part of the planning of vaccine/ intervention trials and epidemiology studies of severe malaria.

In areas of high malaria transmission, the parasitemic thresholds for defining severe disease will increase. Interestingly, in Kilifi, the thresholds defining uncomplicated and severe malaria were similar. If confirmed elsewhere, this raises the possibility that when parasite density thresholds are available for uncomplicated malaria [10] but not for severe disease, the former could potentially be applied to the latter.

Recent studies suggest that 30% of falciparum malaria occurs outside Africa, mostly in South and Southeast Asia [11], and often in areas with lower, unstable transmission where severe disease occurs in adults as well as children. Calculation of MAFs will be required for each of these age groups. In these regions *P. vivax* may account for more than 50% of infections and is a likely cause of a significant yet neglected burden of severe disease, particularly severe anemia in children [12]. A similar approach to defining attributable fractions for *P. vivax* infections as that demonstrated for *P. falciparum* will allow a better appreciation of the relative burden of *P. vivax* and other malaria species whose association with severe morbidity is often dismissed [12].

Finally, while the lengthy descriptions of severe malaria included in current WHO guidelines [3] are appropriate for clinical purposes, they lack clarity for research purposes. This is particularly true for case definitions in adults, resulting in the frequent use of “modified WHO criteria” to define severe malaria in published studies [2,5,13]. A parasite threshold to improve specificity in severe anemia was defined for research purposes in the 1990 WHO guidelines [8], but was dropped from the current WHO guidelines [3]. Forthcoming guidelines should more clearly and concisely establish case definitions for severe malaria in both children and adults, suitable for different research purposes in different epidemiological settings.

For malaria prevention trials and disease burden studies, forthcoming WHO guidelines should highlight the utility of Bejon et al.’s MAF approach in developing locally applicable case definitions of severe malaria.